Latest News and Press Releases
Want to stay updated on the latest news?
-
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical...
-
New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
-
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of...
-
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company...
-
Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Third-Party Logistics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...
-
Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software,...
-
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of...
-
AGT103-T shows HIV reservoir reduction in all patients; one to undetectable. AGT unveils functional cure data at IAS 2025 late-breaker.
-
SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of...
-
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...